Floatz logo

Quisinostat

Lymphoma, T-Cell, Cutaneous

Janssen Research & Development, LLCSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Lymphoma, T-Cell, Cutaneous cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Inno-206
Falo, Louis, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

Quisinostat is also rated in:

uveal melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
ovarian cancerDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →